COMMUNIQUÉS West-GlobeNewswire

CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

01/05/2019 - 13:25

OXNARD, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced [...]

Apollomics, Inc. Appoints Fabio M. Benedetti, M.D. as Chief Medical Officer

01/05/2019 - 13:10

FOSTER CITY, Calif. and HANGZHOU, China, May 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination [...]

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

01/05/2019 - 13:05

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare [...]

Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings

01/05/2019 - 13:05

- SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and subretinal surgery - [...]

EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

01/05/2019 - 13:00

– 36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes - – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass., May 01 [...]

C-RAD Web Presentation Interim Report Q1 2019

01/05/2019 - 08:30

Presentation of the report for the first quarter of the fiscal year 2019: Date: Wednesday May 8, 2019 / kl. 13:00 Venue: Online Presentation Topic: C-RAD Interim Report Q1 2019 Procedure: Please register online through [...]

Ambu A/S: Interim report for Q2 2018/19 and for the period 1 October 2018 - 31 March 2019

01/05/2019 - 08:01

Ambu realised organic growth of 14% in Q2 and an increase in earnings of 25%, resulting in an EBIT margin of 24.8%. Organic growth of 15% was posted for H1. "Overall, this was Ambu's best-ever quarter. Growth of 21% in [...]

Motif Bio Signs Agreement with Lamellar Biomedical

01/05/2019 - 08:00

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising [...]

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

01/05/2019 - 08:00

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment [...]

Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update

01/05/2019 - 08:00

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its [...]

Interim Report Q1 2019: Strong start to 2019 with 19% organic revenue growth and 25% EPS increase in Q1

01/05/2019 - 07:00

GN delivered 19% organic revenue growth in Q1 2019. Revenue growth was 24% including around 3% impact from the development in foreign exchange rates and around 1% impact from M&A EBITA margin increased to 15.5% [...]

ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

01/05/2019 - 07:00

Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]

Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)

01/05/2019 - 07:00

Marseille, France, May 1, 2019, 7:00 AM CEST Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 22, 2019, at 11:00 AM in its [...]

Innate Pharma annonce la tenue de son Assemblée Générale Annuelle le 22 mai 2019 à Marseille et la mise à disposition de son Document de Référence 2018

01/05/2019 - 07:00

Marseille, le 1 er mai 2019, 7h00 Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la tenue de son Assemblée Générale annuelle le 22 mai 2019 à 11 heures, au siège social de la Société, situé au 117, avenue [...]

Initiation of new share buyback program

01/05/2019 - 06:55

Based on the continued solid business performance and GN’s capital structure policy and in accordance with the authorization granted to the Board of Directors at the annual general meeting on 21 March 2019, GN announces [...]

Veteran With Spinal Injury to Throw Out First Pitch at Diamondbacks Game Tuesday Thanks to SoldierStrong-Donated Exoskeleton

01/05/2019 - 04:21

PHOENIX, April 30, 2019 (GLOBE NEWSWIRE) -- Dan Rose, a former U.S. Army sergeant paralyzed by an 1,100-pound bomb in Afghanistan in 2011, will throw out the first pitch at Tuesday's Arizona Diamondbacks-New York [...]

SoldierStrong Donates State-of-the-Art Exoskeleton to the Veterans Affairs Phoenix Health Care System

01/05/2019 - 04:10

PHOENIX, April 30, 2019 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit organization dedicated to providing advanced medical technologies to veterans, donated an EksoGT Suit exoskeleton to the Phoenix Veterans [...]

À l'occasion de l'assemblée générale annuelle de l'American Society of Gene and Cell Therapy, Abeona Therapeutics présentera de nouvelles données précliniques démontrant le potentiel thérapeutique d'ABO-401 pour le traitement de la fibrose kystique

01/05/2019 - 03:05

NEW YORK et CLEVELAND, 01 mai 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), un chef de file totalement intégré en thérapie génique et cellulaire, présentera aujourd'hui de nouvelles données [...]

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injection

01/05/2019 - 02:16

Issues related to facility inspections and manufacturing deficiencies at one contract manufacturer Conference call and webcast tomorrow at 8:00 a.m. EDT DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva [...]